private-startup · therapeutic · neurostimulation
Flow Neuroscience
At a glance
- Legal name
- —
- Aliases
- —
- Type
- private-startup
- Focus areas
- therapeutic, neurostimulation, consumer-wellness, clinical-grade
- Founded
- Defunct
- —
- Spinout of
- —
- HQ city
- Malmö
- HQ country
- SE
- Employees
- —
- Flagship device
- flow-neuroscience-headset
- Product lines
- 1
- In-house manufacturing
- —
- Open source
- No
- GitHub org
- —
- Website
- flowneuroscience.com
- Blog
- —
- Support
- help.flowneuroscience.com
Devices
People
Founders
Daniel Mansson
Co-Founder, CEO
Erik Rehn
Co-Founder
Current leadership
Daniel Mansson
CEO
Kultar Garcha
Chief Medical Officer
Milestones
Flow Neuroscience founded in Malmö
CE-MDR Class IIa clearance
CE Class IIa medical-device clearance for adult major depressive disorder in Europe and the UK.
Nature Medicine RCT publishes positive results
Randomised sham-controlled trial showing remission and response benefits over 10 weeks of home tDCS use.
FDA PMA approval (P230024) for the Flow FL-100
First at-home tDCS device approved by the FDA for the treatment of major depressive disorder in adults; US launch planned Q2 2026.
Reputation
Widely regarded as the most clinically-credible consumer-form-factor brain-stim company. Daniel Mansson is a registered clinical psychologist and frequently presents Flow's RCT evidence at academic depression-treatment conferences. Distinct from the DIY / biohacker tDCS scene by virtue of the medical-device pathway and prescription-clinician model.